3646 results for «722»
3646 results
AI adoption in the cathlab of tomorrow - Risk prediction applications
20 May 2026 – From EuroPCR 2026
This session delves into the adoption of artificial intelligence in the cath lab, focusing on clinically useful risk prediction models for coronary and structural interventions. It covers advanced AI-guided intravascular imaging, machine learning applications for adverse event prediction, and critical evaluation of model validation and clinical...
Complex endovascular and pulmonary interventions
20 May 2026 – From EuroPCR 2026
Explore advances in complex endovascular and pulmonary interventions, including the transformation of interventional labs into intelligent learning ecosystems, innovative approaches to peripheral and coronary CTOs, and novel therapies such as extravascular renal denervation and fixation catheters for acute pulmonary embolism.
Mitral paravalvular leak closure: case-bases strategies
20 May 2026 – From EuroPCR 2026
This session presents case-based strategies for mitral paravalvular leak closure, highlighting complex percutaneous approaches including multivalvular failure management, apical access techniques, and transatrial direct surgical valve-in-MAC procedures. It features challenging clinical scenarios demonstrating innovative solutions for hemolytic leaks and complex paravalvular defects.
Management of rare clinical scenarios in the cathlab
20 May 2026 – From EuroPCR 2026
This session addresses the management of rare and complex clinical scenarios encountered in the catheterization laboratory. Cases include dyspnea in coronary artery bypass graft patients, aortocoronary dissection management, complications during coronary sinus reducer implantation, coronary artery aneurysms related to IgG4 vasculitis, ibuprofen-induced Kounis syndrome, and challenging...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
